{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:24:45Z","timestamp":1787185485498,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation General Program of Guangdong Province, China","award":["2021A1515010764"],"award-info":[{"award-number":["2021A1515010764"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56230-0","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T20:45:25Z","timestamp":1780951525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of genomic profiles and clinical outcomes in cholangiocarcinoma and gallbladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Weiqun","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuicui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaohui","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"56230_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio, P. et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J. Hepatol. 71, 104\u2013114 (2019).","journal-title":"J. Hepatol."},{"key":"56230_CR2","first-page":"99","volume":"6","author":"R Hundal","year":"2014","unstructured":"Hundal, R. & Shaffer, E. A. Gallbladder cancer: Epidemiology and outcome. Clin. Epidemiol. 6, 99\u2013109 (2014).","journal-title":"Clin. Epidemiol."},{"key":"56230_CR3","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1634\/theoncologist.2009-0302","volume":"15","author":"AX Zhu","year":"2010","unstructured":"Zhu, A. X., Hong, T. S., Hezel, A. F. & Kooby, D. A. Current management of gallbladder carcinoma. Oncologist 15, 168\u2013181 (2010).","journal-title":"Oncologist"},{"key":"56230_CR4","doi-asserted-by":"publisher","first-page":"955","DOI":"10.21873\/anticanres.11404","volume":"37","author":"I Marinelli","year":"2017","unstructured":"Marinelli, I. et al. Clinical target volume in biliary carcinoma: A systematic review of pathological studies. Anticancer Res. 37, 955\u2013961 (2017).","journal-title":"Anticancer Res."},{"key":"56230_CR5","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros, M. N., Economopoulos, K. P., Alexiou, V. G. & Pawlik, T. M. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: Systematic Review and meta-analysis. JAMA Surg. 149, 565\u2013574 (2014).","journal-title":"JAMA Surg."},{"key":"56230_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/1120009X.2021.1953887","volume":"34","author":"R Filippi","year":"2022","unstructured":"Filippi, R. et al. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: A real-world analysis. J. Chemother. 34, 123\u2013132 (2022).","journal-title":"J. Chemother."},{"key":"56230_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jhep.2018.02.029","volume":"69","author":"LQ Dong","year":"2018","unstructured":"Dong, L. Q. et al. Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. J. Hepatol. 69, 89\u201398 (2018).","journal-title":"J. Hepatol."},{"key":"56230_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21873\/cgp.20203","volume":"17","author":"A Rizzo","year":"2020","unstructured":"Rizzo, A., Ricci, A. D., Tavolari, S. & Brandi, G. Circulating tumor DNA in biliary tract cancer: Current evidence and future perspectives. Cancer Genomics Proteom. 17, 441\u2013452 (2020).","journal-title":"Cancer Genomics Proteom."},{"key":"56230_CR9","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers. Nat. Commun. 13, 3061 (2022).","journal-title":"Nat. Commun."},{"key":"56230_CR10","doi-asserted-by":"publisher","first-page":"153806","DOI":"10.1016\/j.prp.2022.153806","volume":"232","author":"S Mishra","year":"2022","unstructured":"Mishra, S. et al. Genomic profiling of gallbladder carcinoma: Targetable mutations and pathways involved. Pathol. Res. Pract. 232, 153806 (2022).","journal-title":"Pathol. Res. Pract."},{"key":"56230_CR11","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","volume":"24","author":"MA Lowery","year":"2018","unstructured":"Lowery, M. A. et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: Potential targets for intervention. Clin. Cancer Res. 24, 4154\u20134161 (2018).","journal-title":"Clin. Cancer Res."},{"key":"56230_CR12","doi-asserted-by":"publisher","first-page":"101998","DOI":"10.1016\/j.ctrv.2020.101998","volume":"86","author":"A Athauda","year":"2020","unstructured":"Athauda, A. et al. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat. Rev. 86, 101998 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"56230_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"56230_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 21, 796\u2013807 (2020).","journal-title":"Lancet Oncol."},{"key":"56230_CR15","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-22-1954","volume":"28","author":"NA Giraldo","year":"2022","unstructured":"Giraldo, N. A. et al. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin. Cancer Res. 28, 5359\u20135367 (2022).","journal-title":"Clin. Cancer Res."},{"key":"56230_CR16","unstructured":"Chalmers, Z. R. et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 9, 34 (2017)."},{"key":"56230_CR17","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1158\/1078-0432.CCR-19-0585","volume":"25","author":"W Fang","year":"2019","unstructured":"Fang, W. et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin. Cancer Res. 25, 5015\u20135026 (2019).","journal-title":"Clin. Cancer Res."},{"key":"56230_CR18","unstructured":"U.S. Food and Drug Administration. 510(k) Substantial Equivalence Determination Decision Summary: GENESEEQPRIME NGS Tumor Profiling Assay (FFPE) (GS6005) (U.S. Food and Drug Administration, 2025)."},{"key":"56230_CR19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/cam4.3765","volume":"10","author":"X Zhang","year":"2021","unstructured":"Zhang, X. et al. Distinct genomic profile in H. pylori-associated gastric cancer. Cancer Med. 10, 2461\u20132469 (2021).","journal-title":"Cancer Med."},{"key":"56230_CR20","doi-asserted-by":"publisher","first-page":"e6796","DOI":"10.1002\/cam4.6796","volume":"13","author":"L Han","year":"2024","unstructured":"Han, L. et al. Comprehensive characterization of PKHD1 mutation in human colon cancer. Cancer Med. 13, e6796 (2024).","journal-title":"Cancer Med."},{"key":"56230_CR21","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"56230_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-023-02768-z","volume":"21","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes. BMC Med. 21, 73 (2023).","journal-title":"BMC Med."},{"key":"56230_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ijrobp.2022.07.1835","volume":"115","author":"L Li","year":"2023","unstructured":"Li, L. et al. Clinical outcome-related cancer pathways and mutational signatures in patients with unresectable esophageal squamous cell carcinoma treated with chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 115, 382\u2013394 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"56230_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289\u2013300 (1995).","journal-title":"J. Roy. Stat. Soc.: Ser. B (Methodol.)"},{"key":"56230_CR25","first-page":"275","volume":"18","author":"M Stephens","year":"2017","unstructured":"Stephens, M. False discovery rates: A new deal. Biostatistics 18, 275\u2013294 (2017).","journal-title":"Biostatistics"},{"key":"56230_CR26","doi-asserted-by":"crossref","unstructured":"Storey, J. D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. 100, 9440\u20139445 (2003).","DOI":"10.1073\/pnas.1530509100"},{"key":"56230_CR27","unstructured":"Knijnenburg, T. A. et al. Genomic and molecular landscape of dna damage repair deficiency across the cancer genome atlas. Cell Rep. 23, 239\u2013254 (2018)."},{"key":"56230_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","volume":"47","author":"H Nakamura","year":"2015","unstructured":"Nakamura, H. et al. Genomic spectra of biliary tract cancer. Nat. Genet. 47, 1003\u20131010 (2015).","journal-title":"Nat. Genet."},{"key":"56230_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell, C. P. et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J. Hepatol. 68, 959\u2013969 (2018).","journal-title":"J. Hepatol."},{"key":"56230_CR30","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.7150\/thno.56539","volume":"11","author":"J Lin","year":"2021","unstructured":"Lin, J. et al. Mutational spectrum and precision oncology for biliary tract carcinoma. Theranostics 11, 4585\u20134598 (2021).","journal-title":"Theranostics"},{"key":"56230_CR31","doi-asserted-by":"publisher","first-page":"930611","DOI":"10.3389\/fonc.2022.930611","volume":"12","author":"H Yu","year":"2022","unstructured":"Yu, H. et al. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front. Oncol. 12, 930611 (2022).","journal-title":"Front. Oncol."},{"key":"56230_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41698-023-00409-5","volume":"7","author":"K Zimmer","year":"2023","unstructured":"Zimmer, K. et al. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. NPJ Precis. Oncol. 7, 64 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"56230_CR33","doi-asserted-by":"publisher","first-page":"712765","DOI":"10.3389\/fonc.2021.712765","volume":"11","author":"A Aili","year":"2021","unstructured":"Aili, A., Wen, J., Xue, L. & Wang, J. Mutational analysis of PBRM1 and significance of PBRM1 mutation in anti-PD-1 immunotherapy of clear cell renal cell carcinoma. Front. Oncol. 11, 712765 (2021).","journal-title":"Front. Oncol."},{"key":"56230_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/cancers12010016","volume":"12","author":"L Carril-Ajuria","year":"2019","unstructured":"Carril-Ajuria, L., Santos, M., Roldan-Romero, J. M., Rodriguez-Antona, C. & de Velasco, G. Prognostic and predictive value of PBRM1 in clear cell renal cell carcinoma. Cancers 12, 16 (2019).","journal-title":"Cancers (Basel)"},{"key":"56230_CR35","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1111\/bju.12426","volume":"113","author":"WH da Costa","year":"2014","unstructured":"da Costa, W. H. et al. Polybromo-1 (PBRM1), a SWI\/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma. BJU Int. 113, E157\u2013E163 (2014).","journal-title":"BJU Int."},{"key":"56230_CR36","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"56230_CR37","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"56230_CR38","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1158\/1078-0432.CCR-20-0458","volume":"26","author":"A Osipov","year":"2020","unstructured":"Osipov, A. et al. Tumor mutational burden, toxicity, and response of immune checkpoint inhibitors targeting PD(L)1, CTLA-4, and combination: A meta-regression analysis. Clin. Cancer Res. 26, 4842\u20134851 (2020).","journal-title":"Clin. Cancer Res."},{"key":"56230_CR39","doi-asserted-by":"publisher","first-page":"153303382110623","DOI":"10.1177\/15330338211062324","volume":"20","author":"H Kim","year":"2021","unstructured":"Kim, H. et al. Tumor mutational burden as a biomarker for advanced biliary tract cancer. Technol. Cancer Res. Treat. 20, 15330338211062324 (2021).","journal-title":"Technol. Cancer Res. Treat."},{"key":"56230_CR40","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1535-7163.MCT-20-0161","volume":"19","author":"P Riviere","year":"2020","unstructured":"Riviere, P. et al. High tumor mutational burden correlates with longer survival in immunotherapy-naive patients with diverse cancers. Mol. Cancer Ther. 19, 2139\u20132145 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"56230_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-023-01529-2","volume":"15","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: A systematic review and meta-analysis. Clin. Epigenetics 15, 113 (2023).","journal-title":"Clin. Epigenetics"},{"key":"56230_CR42","doi-asserted-by":"publisher","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","volume":"13","author":"W Tian","year":"2022","unstructured":"Tian, W. et al. Recent advances of IDH1 mutant inhibitor in cancer therapy. Front. Pharmacol. 13, 982424 (2022).","journal-title":"Front. Pharmacol."},{"key":"56230_CR43","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1158\/1078-0432.CCR-20-1888","volume":"27","author":"RG Vile","year":"2021","unstructured":"Vile, R. G., Melcher, A., Pandha, H., Harrington, K. J. & Pulido, J. S. APOBEC and cancer viroimmunotherapy: Thinking the unthinkable. Clin. Cancer Res. 27, 3280\u20133290 (2021).","journal-title":"Clin. Cancer Res."},{"key":"56230_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-023-01425-5","volume":"16","author":"K Butler","year":"2023","unstructured":"Butler, K. & Banday, A. R. APOBEC3-mediated mutagenesis in cancer: Causes, clinical significance and therapeutic potential. J. Hematol. Oncol. 16, 31 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"56230_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/carcin\/bgm247","volume":"29","author":"WY Huang","year":"2008","unstructured":"Huang, W. Y. et al. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: A population-based case-control study in China. Carcinogenesis 29, 100\u2013105 (2008).","journal-title":"Carcinogenesis"},{"key":"56230_CR46","doi-asserted-by":"crossref","unstructured":"Dananberg, A., Striepen, J., Rozowsky, J. S. & Petljak, M. APOBEC mutagenesis in cancer development and susceptibility. Cancers 16, 374 (2024).","DOI":"10.3390\/cancers16020374"},{"key":"56230_CR47","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jhep.2022.09.025","volume":"78","author":"Y Okawa","year":"2023","unstructured":"Okawa, Y. et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J. Hepatol. 78, 333\u2013342 (2023).","journal-title":"J. Hepatol."},{"key":"56230_CR48","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/jnci\/djs351","volume":"104","author":"AK Win","year":"2012","unstructured":"Win, A. K. et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J. Natl. Cancer Inst. 104, 1363\u20131372 (2012).","journal-title":"J. Natl. Cancer Inst."},{"key":"56230_CR49","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1093\/jnci\/djy085","volume":"110","author":"MM Hoppe","year":"2018","unstructured":"Hoppe, M. M., Sundar, R., Tan, D. S. P. & Jeyasekharan, A. D. Biomarkers for homologous recombination deficiency in cancer. J. Natl. Cancer Inst. 110, 704\u2013713 (2018).","journal-title":"J. Natl. Cancer Inst."},{"key":"56230_CR50","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.21037\/jgo-23-425","volume":"14","author":"JT Smith","year":"2023","unstructured":"Smith, J. T., Sama, S., Florou, V., Nevala-Plagemann, C. & Garrido-Laguna, I. Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: Case report. J. Gastrointest. Oncol. 14, 2637\u20132643 (2023).","journal-title":"J. Gastrointest. Oncol."},{"key":"56230_CR51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.029","volume":"516","author":"AR Nam","year":"2021","unstructured":"Nam, A. R. et al. ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer. Cancer Lett. 516, 38\u201347 (2021).","journal-title":"Cancer Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56230-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56230-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:40:17Z","timestamp":1787182817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56230-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56230"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56230-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cuicui Liu, Jiaohui Pang, and Jiani Yin are employees of Nanjing Geneseeq Technology Inc. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Medical Ethics Committee of Geneseeq Medical Laboratory (NSJB-MEC-2022-02). Written informed consent was obtained from all participants prior to sample collection.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent form was obtained from each patient.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"26135"}}